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Background: Despite Southern Norway is an endemic area for Lyme borreliosis there is a lack of data on Lyme
arthritis (LA). In the literature controversies exist if acute LA can develop into chronic arthritis. Our objective was to
identify and characterize patients with LA in Southern Norway and explore disease course after antibiotic treatment.
Methods: Patients aged 20 years or older with arthritis and a positive serology for Borrelia burgdorferi infection
(IgG and/or IgM) suspected of having LA were consecutively recruited either from general practitioners or from
hospital departments.
Results: From January 2007 to December 2010 a total of 27 patients were assessed. Mean (range) age was 56 years
(41–80) and mean symptom duration prior to inclusion was 11.2 weeks (1 day – 2 years). Definite LA was
diagnosed in 16 patients, probable LA in 5 patients and 6 patients were concluded to have other arthritis disorders.
Among the 21 LA patients 20 had mono-arthritis (knee 18, ankle 2) and 1 had polyarthritis.
All LA patients responded favourable to antibiotic treatment and none of the patients developed chronic arthritis
after long term follow up, not even in LA patients who had intraarticular glucocorticosteroid (GC) injection prior to
antibiotic treatment.
Conclusions: Our data shows that LA in Southern Norway is a benign disease which successfully can be treated
with antibiotics even in patients treated with GC prior to antibiotics.Background
Lyme borreliosis is caused by the spirochete Borrelia
burgdorferi sensu lato (Bb) and is the most common
tick-borne disease in the northern hemisphere [1]. The
coastal part of Southern Norway is known as an endemic
area for Lyme borreliosis [2]. In this area, Ixodes ricinus
ticks are prevalent and Bb is found in about 25% of
the ticks [3] and IgG antibodies against Bb is found in
approximately 20% of the adult population [4].
The main attention in Norway on Bb infections has
been on Lyme neuroborreliosis [5-8]. Despite arthritis
being a well-known manifestation of Bb infection, there
is a lack of data on Lyme arthritis (LA) in Norway. In
the literature there are controversies whether LA after
antibiotic treatment can develop into chronic arthritis* Correspondence: glenn.haugeberg@sshf.no
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article, unless otherwise stated.[9,10]. Our clinical experience has been that LA is suc-
cessfully treated with antibiotics without causing chronic
arthritis even in patients treated with GC prior to anti-
biotic treatment.
Thus our aim was prospectively to identify and cha-
racterize patients with LA in Southern Norway in a long
term follow up study and to illuminate treatment response
to antibiotic in these patients.Methods
Recruitment of patients and collection of clinical data
Patients suspected of having LA were consecutively
recruited from Southern Norway. The patients were
assessed at the outpatient rheumatology clinic at the
Hospital of Southern Norway Trust in Kristiansand. In
2007 the hospital covered a population of 268 461 in-
habitants (195 492 inhabitants aged above 20 years).
Patients aged ≥ 18 years with acute arthritis with a
positive Bb laboratory test suspected to have LA were
consecutively assessed and included. A positive Bb test
was defined by the presence of serum IgG and/or IgMtral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
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chain reaction (PCR) test for Bb in synovial fluid. The
patients were either recruited from general practitioners
who referred arthritis patients with a positive serology
or from our own rheumatology department.
Data on demographic and clinical characteristics were
collected. Clinical data collection included history of previ-
ous tick bite(s) and erythema migrans, duration of arthritis,
joint(s) affected, and previous anti-inflammatory treatment
including intra-articular injections of glucocorticosteroids
(GC). Microscopy and white blood cell count in synovial
fluid was also performed when joint fluid was available.
Data for erythrocyte sedimentation rate (ESR), C-reactive
protein (CRP), was also collected.
Treatment and treatment effect during follow up was
recorded. The included patients were followed in the out-
patient clinic by experienced rheumatologists. All assessed
patients were also informed to take direct contact with the
rheumatology outpatient clinic in case of recurrent joint
symptoms.
Definition of definite and probable Lyme arthritis
Definite LA was defined by the presence of arthritis ex-
cluding other arthritis disorders diagnosed by experienced
rheumatologists (IJWH, GH) and the presence of serum
IgG antibodies against Bb and/or a positive PCR test
against Bb in synovial fluid. Probable LA was defined as
presence of arthritis and detected serum IgG antibodies
against Bb and/or a positive PCR test against Bb, however
other diagnosis of arthritis could not be definitely ex-
cluded as the causative factor. No LA was concluded
when arthritis was explained by other obvious rheumatic
joint diseases e.g. osteoarthritis and psoriatic arthritis,
despite the presence of positive Bb serology.
Detection of antibodies to Borrelia burgdorferi sensu lato
Sera were examined for Bb IgM and IgG antibodies by an
EIA using B. garinii (PKo strain) as antigen (Enzygnost
Borreliosis, Dade Behring, Marburg GmbH, Germany)
(EnzygnostM, EnzygnostG). From 18.11.2008 the IgG test
with added VlsE was used (Enzygnost Lyme link VlsE
IgG).
Detection of Borrelia burgdorferi sensu lato
DNA was isolated from joint fluid using (Magnapur).
Purified DNA was stored at -20°C. DNA extracts were
examined for Bb spirochetes by using a real-time PCR
with probe (FAM-5’-TTCGGTACTAACTTTTAGTTAA-
MGBNFQ) and primers (forward and reverse primer se-
quences were 5’GCTGTAAACGATGCACACTTGGTand
5’GGCGGCACACTTAACACGTTAG, respectively) spe-
cific for a section of the 16S ribosomal RNA (rRNA)
gene [11]. Real-time PCR was performed as previously
described [3]. Briefly, real-time PCR was performed usingiCycler/MyIQTM (Bio-Rad). The 25 μl PCR mixture
included 1X ready-to-use reaction mixture (TaqMan
Universal PCR Master Mix, Applied Biosystems Inc.)
which contains reaction buffer, Taq DNA polymerase,
deoxynucleoside triphosphate and MgCl2. The final
concentration of the primers and probe were 1.125 μM
and 0.25 μM, respectively. Finally, 5 μl of template
DNA was added. The PCR conditions were as follows:
50°C for 2 min and 95°C for 10 min, followed by 50 cy-
cles of 95°C for 15 s and 63°C for 60 s. Differentiation
of Bb strains was done by a species specific, single run,
real-time PCR based on the protein HBb (hbb) gene se-
quence [12] as previously described [3]. The melting
points of the amplicons generated from the unknown
samples and from known Bb species were compared
for genotyping. In cases where a clear identification
could not be made, genotyping was done by direct se-
quencing of the chromosome located rrs (16S) – rrlA
(23S) intergenic spacer (IGS) [13]. PCR and sequencing
were performed as previously described [3]. Negative
and positive samples were included in all runs. Precau-
tions were taken at all steps of analysis to avoid contamin-
ation of samples.
Statistics
Descriptive statistics was applied and analysed by SPSS for
windows, version 16. Continuous variables were presented
as mean with range in parentheses and categorical vari-
ables as numbers and percentages (%).
Ethics
The study was approved by the ethical committee for
Southern Norway Helse Sør (REK S-06474a). All patients
gave written informed consent before inclusion.
Results
From January 2007 to December 2010 a total of 27 patients
suspected to have LA were assessed at the outpatient clinic.
Mean age was 56 years (41–80). Mean symptom duration
prior to assessment at the outpatient rheumatology clinic
was 11.2 weeks (1 day – 2 years).
Definite LA was diagnosed in 16 patients (10 men, 6
females), probable LA in 5 patients (3 men and 2 females)
and no LA in 6 patients (2 rheumatoid arthritis, 2 psoriatic
arthritis and 2 knee osteoarthritis). In the group of pa-
tients with probable LA 2 patients also had a severe osteo-
arthritis, 2 patients were HLAB27 positive and peripheral
spondyloarthritis could not be excluded, and 1 patient had
a severe osteochondral lesion of the affected ankle joint.
Mean follow up time from inclusion to last visit at the
outpatient clinic for all 27 patients was 70 weeks (range
15–292) and for patients with definite and probable LA
54 weeks (15–152). All medical records from the 27 pa-
tients were finally reviewed in September 2013 and none
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have recurrent arthritis which could be attributed to LA.
A history of prior erythema migrans was reported in 7
of the 27 included patients, 4 in the definite group, 1 in
the probable group and 2 in the group diagnosed not to
have LA. A history of prior tick-bite was reported in 11/16
patients in the definite and 3/5 in the probable LA group
and in all 6 patients in the non LA group.
In Table 1 demographic and disease characteristics are
shown for each single patient with definite and probable
LA. Among the 16 patients with definite arthritis all had
mono-arthritis (knee 15 and ankle 1) and among the 5
patients with probable LA 4 had mono-arthritis (knee 3
and ankle 1) and 1 polyarthritis (both knees and several
small joints in the left foot).
At time of inclusion for the 21 LA patients, the mean
ESR was 31 mm/h (8–68), mean CRP was 43 mg/dl (1–
132) and mean white cell count in synovial fluid available
from 14 patients was 18 G/L (0–101).
The Bb IgG and IgM results for each of the 21 LA pa-
tients are displayed in Table 1. All LA patients who had
been tested (19/21) had high level of serum IgG antibodies
to Bb (mean 1800% of cut off, range 700–2550). The 2
patients who were not tested for antibodies to Bb were
included due to detection of Bb in synovial fluid by PCR
and a clinic suggestive of LA.
Bb IgM antibody tests were positive in 6/16 patients in
the definite group and 2/5 in the probable LA group.
Further 2 patients had an inconclusive serum IgM Bb test.
Among the 15 tested patients in the definite LA group a
positive borrelia PCR test in synovial fluid was found in 11
patients. Among the 5 patients in the probable group and
among the 4 patients in the no LA group tested, none had
a positive Bb PCR test.
Only one patient in the definite LA group with age
68 years with disease duration of 104 weeks (see Table 1)
had several recurrent arthritis flairs before diagnosed as
LA. The other patients with a suggestive history suggestive
of LA had a disease duration that ranged from a few days
to 12 weeks.
Among the LA patients 19 were treated with doxycyc-
line for 2–8 weeks and one patient was treated with
cloxacilline and cefotaxime for 14 days each. This one
patient was initially suspected to have septic arthritis.
The one patient with the long disease duration of 104 weeks
described above was first treated for 3 weeks with doxy-
cycline and thereafter for 4 weeks with doxycycline due to
a more prolonged clinical arthritis.
In the 16 patients with definite LA, 11 patients had no
flares, 3 patients had one and 2 patients had 2 flares.
These flares, apart from in one patient, were episodes of
arthritis symptoms the patients reported the first weeks
and months after antibiotic treatment. In one patient a
more significant flare occurred 3 months after his firsttreatment. He was then treated with a second course of
doxycycline for 4 weeks, thereafter no flare occurred.
None of the patients developed chronic arthritis or re-
current arthritis after long term follow up. Among the 5
patients with probable LA, 2 had no flares, 1 had one flare
and 2 got recurrent episodes of joint effusion. These two
patients also had severe osteoarthritis.
Seven LA patients had intraarticular GC injection
prior to and one during antibiotic treatment. All pa-
tients responded favourable to GC injection however
all relapsed. Conversely, none relapsed after antibiotic
treatment.
Based on the present study, the estimated annual in-
cidence rate for LA in individuals age 20 years or older
in the four years period was 2.7 per 100 000 inhabitants in
the region.
Discussion
In our study we confirm that mono-arthritis in the knee
is the most common manifestation of LA as already rec-
ognized in the first description of LA in 1977 [14]. As
also shown in our patient cohort, other large joints such
as the ankle joint may also be involved, whereas upper
limb large joints and small joins were rarely involved
[14,15]. Further the described recurrent nature of the
LA disease was also seen in our study in 6 out of 16
patients with definite LA and 3 out of 5 patients with
probable LA [14].
We only included adult individuals, which is a limitation
of our study as LA has been reported to be more frequent
in children than in adults [14].
In Norway, all systemic clinical manifestations of Lyme
borreliosis (but not erythema migrans) are notifiable to
the Norwegian Institute of Public Health. In Norway in
the 10 year period from 1995 to 2004 a total of 1 506
cases (annually ranging from 120 to 253) were reported
with Lyme borreliosis other than erythema migrans [2]. In
this report the highest incidence was found in children
aged between 5 and 9 years. Lyme neuroborreliosis was
the most common reported clinical manifestation (71%),
followed by arthritis/arthralgia (22%) and acrodermatitis
chronica atrophicans (5%). In the same geographic area
of Southern Norway where our study was carried out,
an annual incidence rate of Lyme neuroborreliosis of 10
per 100 000 adult inhabitants has been reported [8]. Es-
timated annual incidence rates for LA in adults was in
our study 2.7 per 100 000 inhabitants. However, the
numbers of adult patients with Lyme borreliosis from
Southern Norway reported to the Norwegian Institute
of Public Health was 63 in 2007, 53 in 2008, 29 in 2009
and 23 in 2010, yielding an annual incidence ranging
from approximately 12 to 32 per 100 000 adult inhabi-
tants, with an average annual incidence of 21/100 000
[16]. Thus, the number of identified patients with LA in
Table 1 Characteristics of 16 patients with definite Lyme arthritis and 5 patients with probable Lyme arthritis
Definite
Age
(years) Gender
History of
prior tick
bite
History
of prior
EM
Duration of
arthritis
(weeks) Joint affected
Minor flares
after antibiotic
treatment*
ESR
(mm/h)
CRP
(mg/dl)
Serum Bb IgG
% of cut off
at baseline
Serum Bb IgM
positive test
at baseline
PCR positive
test for Bb
in joint fluid
Intraarticular GC
before antibiotic
therapy
46 Male Yes No 3 Left knee None 32 13 2423 Yes Yes Yes
54 Male Yes No 1 Left knee None 55 89 700 No Yes Yes
47 Female Yes No 1 Right knee One 45 1 1350 Yes Yes No
68 Male Yes No 104 Left knee Two 13 51 1550 Yes Yes Yes
65 Male Yes No 1 Left knee Two 48 129 1200 +/- Yes Yes
70 Female Yes No 7 Right knee None 13 1 1500 No No No
50 Female Yes Yes 3 Left knee None 9 2 2273 Yes No No
49 Male Yes Yes 1 Left ankle None 37 74 2400 No No No
50 Male Yes Yes 1 Right knee None 23 33 2335 Yes NA Yes
59 Male Yes No 3 Left knee One 32 13 2423 Yes No No
54 Female No No 1.5 Left knee None 9 1 1350 No Yes Yes
55 Male No No 12 Right knee One 38 24 1350 No Yes Yes
66 Male No No 2.5 Right knee None 67 NA NA Yes No
51 Female Yes Yes 12 Right knee None 20 1 1450 No Yes No
50 Female No No 5 Left knee None 15 30 NA NA Yes No
47 Male No No 2 Left knee None 29 93 1300 +/- Yes No
Probable
Age
(years) Gender
History of
prior tick
bite
History
of prior
EM
Duration of
arthritis
(weeks) Joint affected
Minor flares
after antibiotic
treatment*
ESR
(mm/h)
CRP
(mg/dl)
Serum Bb IgG
% of cut off at
baseline
Serum Bb IgM
positive test at
baseline
PCR positive
test for Bb
injointfluid
Intraarticular GC
before antibiotic
therapy
41 Male Yes No 0 Left ankle None 8 53 2100 No No No
80 Male No No 3 Left knee † 35 3 2550 No No No
53 Female Yes No 2
Both knees and several
small joints in left foot
(MTP and PIP-joints) One 68 90 2500 No No No
50 Male No No 0 Right knee None 68 132 1750 Yes No No
56 Female Yes Yes 4 Left knee † 15 1 1300 Yes No No
EM: Erythema migrans. ESR: Erythrocyte sedimentation rate. CRP: C-reactive protein. Bb: Borrelia burgdorferi. IgG: Immunoglobulin type G. IgM: Immunoglobulin type M. PCR: Polymerase chain reaction. GC: Glucocorticosteroids.
NA: Not assessed. MTP: Metatarsophalangeal joints. PIP: Proximal interphalangeal joints.
*Defined as episodes of arthritis symptoms the patients reported the first weeks/months after antibiotic treatment.
+/- Non conclusive test.
†Concomitant osteoarthritis with recurrent episodes of joint effusion.
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number of patients in this geographical area. In a study
estimating the incidence of Lyme borreliosis in the
county of Westchester, New York in US the incidence
was estimated to be several fold higher than suggested
by the reporting system [17]. In our geographical area
patients with LA most likely have been treated by general
practitioners, and some patients may have been treated by
the two private practicing rheumatologists working in the
hospital area. Another reason may be that patients only
had a short episode of arthritis and that signs and symp-
toms then spontaneously disappeared and thus were not
referred. Minor transient attacks with arthritis were also
observed in the cohort of untreated LA patients described
by Steere and colleges [15].
The clinical signs and symptoms seen in LA are not
diagnostically specific for the disease. Prior to the avail-
ability of laboratory tests, patients with LA were fre-
quently diagnosed e.g. as reactive arthritis and RA in
adults and as pauciarticular juvenile arthritis in children
[15]. The use of laboratory tests detecting antibodies
against Bb has improved sensitivity and specificity diag-
nosing LA. PCR techniques have also become available
to detect borrelial DNA directly in synovial fluid. However
the concomitant presence of antibodies against Bb and
other inflammatory joint diseases may be a challenge diag-
nosing these patients. This was also seen in our patient co-
hort of 27 patients where 16 patients were found to have
definite and 5 patients a probable LA. In the later group 2
patients also had severe knee osteoarthritis, 2 patients
were HLAB-27 positive and one patient also developed a
severe osteochondral lesion of the affected ankle joint.
The best description of the natural clinical evolution
of LA in patients with erythema migrans was described
by Steere and colleges in the 1980s [15]. In this cohort
of patients with erythema migrans not treated with anti-
biotics, who were followed longitudinally for a mean
duration of 6 years, approximately 60% developed arth-
ritis. No arthritis was observed in 20% and 18% had only
brief episodes of joint and muscular pain. In the arthritis
group 51% had one episode or began to have intermittent
attacks of frank arthritis whereas 11% of the patients de-
veloped chronic synovitis later in the illness [15]. Acroder-
matitis chronica atrophicans is a well known chronic
manifestation of Lyme borreliosis. Apart from this mani-
festation there are major controversies whether there is a
chronic form of Lyme disease and if there is a subgroup of
patients who require long term antibiotic treatment be-
yond 1–2 months [9,18]. All attempts to illuminate this
possibility have not revealed any objective evidence of
such a hypothesized link between an on-going, active in-
fection with Bb, and chronic clinical signs and symptoms
[9,19]. None of our LA patients with mean follow up of
54 weeks developed chronic arthritis and all patients weresuccessfully treated with antibiotics. In the literature how-
ever, 10% of the LA patients has been reported to develop
chronic arthritis [10]. This may be explained by other
chronic arthritis diseases or by an actual intractable chronic
arthritis not responding to antibiotic treatment.
The administration of intraarticular GC prior to anti-
biotic treatment in LA is not recommended. In a study
by Bentas and colleges they found that patients who had
received intraarticular GC prior to antibiotic treatment
required significantly more courses of antibiotic treatment
and the time required for disappearance of the arthritis
was longer [20]. In our study all LA patients treated with
intraarticular GC injections responded favourably with
temporary relief of clinical signs and symptoms, however
all flared. But, after antibiotic treatment none of the
patients flared or developed chronic arthritis.
Conclusions
LA in Southern Norway seems to be less frequent than
Lyme neuroborreliosis and is a rather benign disease
which is successfully treated with antibiotics even in pa-
tients treated with GC prior to antibiotics. Thus the chal-
lenge is to be aware of the disease, to diagnose LA and
treat the patients properly with recommended antibiotics.
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